Exelixis takes Cabometyx into crowded liver cancer field by Angus Liu Tuesday, January 15, 2019 Exelixis nabbed an FDA nod for Cabometyx in second-line liver cancer, where Stivarga, Opdivo and Keytruda are already battling it out.
Exelixis' Cabometyx nabs first-line nod in kidney cancer by Arlene Weintraub Wednesday, December 20, 2017 Exelixis shares soared Tuesday after its kidney cancer drug won a broader FDA approval expected to push it past $1 billion in peak sales.
